Highlights
• Completion of successful pilot production of AusCann’s final dose form cannabinoid hard shell capsules
• This success enables the move of the production process into a commercial facility in preparation for Australian market and export supply in 2019
• These medicines will then be taken through AusCann’s clinical development program for registration of an approved cannabinoid pain management pharmaceutical product
• Well-funded to execute on its growth strategy following A$35 million Placement during the quarter
Tuesday, 30 October 2018 – Medical cannabinoid pharmaceutical company AusCann Group Holdings Limited (ASX:AC8) (AusCann or ‘the Company’) is pleased to provide an overview of its activities for the three months ended 30 September 2018.
For further information please download PDF attached:
Download this document
